A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients
Abstract
1. This was a randomized, double-blind comparison of the efficacy and safety of venlafaxine and fluoxetine in outpatients with major depression. 2. Three hundred fourteen patients were randomly assigned to either venlafaxine 37.5 mg twice daily or fluoxetine 20 mg once daily for a maximum of 8 weeks. 3. If the response was inadequate after two weeks of treatment, the dosage of venlafaxine could be increased to 75 mg twice daily. 4. A clinical response, defined as at least a 50% decrease from baseline in the total HAM-D score, was attained at week 6 in 72% of patients on venlafaxine and 60% of patients on fluoxetine (p = 0.023). 5. Among patients who increased their dose at 2 weeks, venlafaxine was significantly (p < 0.05) superior from week 3 onward on the HAM-D. 6. Venlafaxine 75 mg daily is comparable to fluoxetine, but at 150 mg daily, it may be superior to fluoxetine in outpatients with major depression who do not respond early to treatment.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Among second generation antidepressants, venlafaxine consistently showed a higher rate of nausea and vomiting than SSRIs.
“Among second generation antidepressants, venlafaxine consistently showed a higher rate of nausea and vomiting than SSRIs.40414243”
From Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review (2018) · cites this paper as [42]
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · see citing works
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · see citing works
(1976) · Medical Entomology and Zoology · Cited by 8,899 · see citing works
Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes
Watson, C. B., & Richelson, E. (1993) · Life Sciences · doi:10.1016/0024-3205(93)90194-8 · Cited by 391 · see citing works
Muth, E. A., Haskins, J. T., Moyer, J. A., Husbands, G. E. M., Nielsen, S. T., & Sigg, E. B. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90769-0 · Cited by 374 · see citing works
Clerc, G. E., Ruimy, P., & Verdeau-Pailles, J. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199409000-00001 · Cited by 301 · see citing works
Pharmacokinetics of antidepressants: why and how they are relevant to treatment.
Cummings, J. L. (1993) · PubMed · Cited by 263 · see citing works
Wood, A. J. J., & Gram, L. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312008 · Cited by 192 · see citing works
Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia.
Guelfi, J., White, C. M., Hackett, D., Guichoux, J. Y., & Magni, G. (1995) · PubMed · Cited by 170 · see citing works
A Comparison of Venlafaxine, Trazodone, and Placebo in Major Depression
Cunningham, L. A., Borison, R. L., Carman, J. S., Chouinard, G., Crowder, J. E., Diamond, B. I., FISCHER, D. E., & HEARST, E. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199404000-00003 · Cited by 157 · see citing works
Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients.
Schweizer, E. E., Feighner, J. P., Mandos, L. A., & Rickels, K. (1994) · PubMed · Cited by 128 · see citing works
Placebo-Controlled Trial of Venlafaxine for the Treatment of Major Depression
Schweizer, E. E., Weise, C., Clary, C. M., Fox, I., & Rickels, K. (1991) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199108000-00002 · Cited by 119 · see citing works
What constitutes an adequate antidepressant trial for fluoxetine?
Schweizer, E. E., Rickels, K., Amsterdam, J. D., Fox, I., Puzzuoli, G., & Weise, C. C. (1990) · PubMed · Cited by 100 · see citing works
The Evidence for 20 mg a day of Fluoxetine as the Optimal Dose in the Treatment of Depression
Altamura, A. C., Montgomery, S., & Wernicke, J. (1988) · The British Journal of Psychiatry · doi:10.1192/s0007125000297377 · Cited by 84 · see citing works
Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study.
MENDELS, J., Johnston, R. B., Mattes, J. A., & Riesenberg, R. A. (1993) · PubMed · Cited by 80 · see citing works
Shrivastava, R. K., Cohn, C., Crowder, J., Davidson, J. R. T., Dünner, D. L., Feighner, J. P., Kiev, A., & Patrick, R. (1994) · PubMed · Cited by 76 · see citing works
Long-Term Safety and Clinical Acceptability of
Shrivastava, R. K., Cohn, C. K., Crowder, J. E., Davidson, J. R. T., Dünner, D. L., Feighner, J. P., Kiev, A., & Patrick, R. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199410000-00006 · Cited by 67 · see citing works
Venlafaxine in depressed outpatients.
Khan, A., Lf, F., & Rudolph, R. L. (1991) · PubMed · Cited by 66 · see citing works
Effect of dose escalation after low-dose fluoxetine therapy.
Dornseif, B. E., Dunlop, S. R., Jh, P., & Jf, W. (1989) · PubMed · Cited by 64 · see citing works
Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose.
D, M. F. M., Rappe, S., Pava, J. A., Nierenberg, A. A., Alpert, J. E., & Rosenbaum, J. F. (1995) · PubMed · Cited by 63 · see citing works
An open-label, dose-finding study of WY-45,030, a novel bicyclic antidepressant.
Schweizer, E. E., Clary, C. M., Weise, C. C., et al. (1988) · PubMed · Cited by 23 · see citing works
An open-label, variable-dose study of WY-45,030 (venlafexine) in depressed outpatients.
Goldberg, H. L., & Finnerty, R. J. (1988) · PubMed · Cited by 19 · see citing works
Introduction. Pharmacokinetics of psychotropic agents: why and how they are relevant to treatment.
Preskorn, S. H. (1993) · PubMed · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · see citing works
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654 · see citing works
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
Vaswani, M., Linda, F. K., & Ramesh, S. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00338-x · Cited by 612 · see citing works
Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K., Lux, L., Van Noord, M., Mager, U., Thieda, P., Gaynes, B. N., Wilkins, T., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-11-201112060-00009 · Cited by 355 · see citing works
Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308 · see citing works
Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
Wang, S.-M., Han, C., Bahk, W.-M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2018) · Chonnam Medical Journal · doi:10.4068/cmj.2018.54.2.101 · Cited by 299 · see citing works
Venlafaxine and paroxetine in treatment-resistant depression: Double-blind, randomised comparison
Poirier, M.-F., & Boyer, P. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.1.12 · Cited by 185 · see citing works
Bielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178 · see citing works
Rudolph, R. L., & Feiger, A. D. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00067-1 · Cited by 158 · see citing works
Gartlehner, G., Thieda, P., Hansen, R. A., Gaynes, B. N., DeVeaugh-Geiss, A., Krebs, E. E., & Lohr, K. N. (2008) · Drug Safety · doi:10.2165/00002018-200831100-00004 · Cited by 150 · see citing works
Third-Generation Antidepressants: Do They Offer Advantages Over the SSRIs?
Olver, J. S., Burrows, G. D., & Norman, T. R. (2001) · CNS Drugs · doi:10.2165/00023210-200115120-00004 · Cited by 63 · see citing works
Mahapatra, S., & Hackett, D. (1997) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.1997.tb11434.x · Cited by 58 · see citing works
Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine
Trivedi, M. H., Desaiah, D., Ossanna, M. J., Pritchett, Y. L., Brannan, S. K., & Detke, M. J. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f41d7e · Cited by 59 · see citing works
- Authors
- Dieric, M., Ravizza, U., Realini, R., & Martin, A.
- Affiliations
- University of Turin (IT)
- Corresponding author
- Dieric, Michel
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 1996-01
- Volume
- 20
- Issue
- 1
- Pages
- 57-71
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W1988861786
- Cited by
- 152
- References
- 23
- Citations by year
- 2024: 2 · 2022: 2 · 2021: 1 · 2020: 1 · 2018: 2 · 2015: 3 · 2014: 1 · 2013: 4 · 2012: 1
- FWCI
- 13.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- venlafaxine, fluoxetine, major depressive disorder, outpatients, antidepressant efficacy, drug safety, dose escalation, treatment response, Hamilton Depression Rating Scale
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Aged, Cyclohexanols, Depressive Disorder, Double-Blind Method, Female, Fluoxetine, Humans, Male, Middle Aged, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
